L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:675777 CAPLUS <<LOGINID::20080113>>
DOCUMENT NUMBER: 147:64481
TITLE: Methods of screening agents for activity using teleosts
INVENTOR(S): McGrath, Patricia; Parng, Chuenlei; Serbedzija, George N.
PATENT ASSIGNEE(S): Phylonix Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 74pp., Cont.-in-part of U.S. Ser. No. 678,765.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007143865	A1	20070621	US 2006-515355	20060901
US 6299858	B1	20011009	US 1999-255397	19990222 <--
EP 1548123	A1	20050629	EP 2005-1508	19990222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 6656449	B1	20031202	US 2000-645432	20000823 <--
US 2004062712	A1	20040401	US 2003-678765	20031002 <--
US 2006104905	A1	20060518	US 2005-280849	20051115

PRIORITY APPLN. INFO.:

US 1998-75783P	P	19980223
US 1998-100950P	P	19980918
US 1999-255397	A2	19990222
US 2000-645432	A1	20000823
US 2003-678765	A2	20031002
EP 1999-934309	A3	19990222
US 2001-947635	A1	20010905

ABSTRACT:
The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity in teleosts are provided. Methods of screening an agent including a drug for an activity in the brain or central nervous system in zebrafish are provided. The invention further provides high throughput methods of screening agents in multi-well plates. Functional blood-brain barrier (BBB) was present in embryo zebrafish demonstrating it's usefulness for screening agents for BBB permeability.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007143865	A1	20070621	US 2006-515355	20060901
	US 6299858	B1	20011009	US 1999-255397	19990222 <--
	EP 1548123	A1	20050629	EP 2005-1508	19990222 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6656449	B1	20031202	US 2000-645432	20000823 <--
	US 2004062712	A1	20040401	US 2003-678765	20031002 <--
	US 2006104905	A1	20060518	US 2005-280849	20051115

IT ***50-02-2***, Dexamethasone 302-79-4, Retinoic acid 23110-15-8D, Fumagillin, derivative 629627-77-6, Ovicillin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)
IT 50-81-7, Ascorbic acid, biological studies 53-06-5, Cortisone 59-02-9, α-Tocopherol 70-51-9, Deferoxamine 91-56-5, Isatin 348-67-4,

D-Methionine 452-86-8, 4-Methylcatechol 616-91-1, N-Acetyl-L-cysteine
700-06-1, Indole-3-carbinol 2323-36-6, Deprenyl 2682-49-7,
2-Oxothiazolidine 10118-90-8, Minocycline 27138-57-4 50903-99-6,
L-NAME 57828-26-9, Lipoic acid
RL: PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)

IT 50-02-2, Dexamethasone
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)

RN 50-02-2 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



IT 700-06-1, Indole-3-carbinol
RL: PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)

RN 700-06-1 CAPLUS

CN 1H-Indole-3-methanol (CA INDEX NAME)



L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:376660 CAPLUS <<LOGINID::20080113>>

DOCUMENT NUMBER: 138:379207

TITLE: Improved use of antitumoral compound in cancer therapy

INVENTOR(S): Jimeno, Jose; Ruiz Casado, Ana; Lopez Lazaro, Luis; Rowinsky, Eric; Hidalgo, Manuel

PATENT ASSIGNEE(S): Pharmamar S.A., Spain

SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
	WO 2003039571	A1	20030515	WO 2002-US33548		20021021	<--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
	CA 2462502	A1	20030515	CA 2002-2462502		20021021	<--
	AU 2002343548	A1	20030519	AU 2002-343548		20021021	<--
	AU 2002343548	B2	20071108				
	EP 1435988	A1	20040714	EP 2002-780496		20021021	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
	BR 2002013424	A	20041214	BR 2002-13424		20021021	<--
	HU 2004001903	A2	20050128	HU 2004-1903		20021021	<--
	CN 1606449	A	20050413	CN 2002-825666		20021021	<--
	JP 2005509650	T	20050414	JP 2003-541862		20021021	<--
	RU 2306933	C2	20070927	RU 2004-115110		20021021	<--
	MX 2004PA03674	A	20040723	MX 2004-PA3674		20040419	
	IN 2004DN01070	A	20060728	IN 2004-DN1070		20040421	
	NO 2004002035	A	20040518	NO 2004-2035		20040518	
	US 2005004018	A1	20050106	US 2004-492320		20040818	
PRIORITY APPLN. INFO.:				US 2001-348414P	P	20011019	
				WO 2002-US33548	W	20021021	

ABSTRACT:
Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003039571	A1	20030515	WO 2002-US33548	20021021	<--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2462502	A1	20030515	CA 2002-2462502	20021021	<--
	AU 2002343548	A1	20030519	AU 2002-343548	20021021	<--
	AU 2002343548	B2	20071108			
	EP 1435988	A1	20040714	EP 2002-780496	20021021	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
	BR 2002013424	A	20041214	BR 2002-13424	20021021	<--
	HU 2004001903	A2	20050128	HU 2004-1903	20021021	<--
	CN 1606449	A	20050413	CN 2002-825666	20021021	<--
	JP 2005509650	T	20050414	JP 2003-541862	20021021	<--
	RU 2306933	C2	20070927	RU 2004-115110	20021021	<--
	MX 2004PA03674	A	20040723	MX 2004-PA3674	20040419	
	IN 2004DN01070	A	20060728	IN 2004-DN1070	20040421	
	NO 2004002035	A	20040518	NO 2004-2035	20040518	
	US 2005004018	A1	20050106	US 2004-492320	20040818	

IT ***114899-77-3***, Ecteinascidin 743

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

IT ***50-02-2*** 15663-27-1, Cisplatin 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

IT ***114899-77-3***, Ecteinascidin 743
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

RN 114899-77-3 CAPLUS

CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT ***50-02-2***
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

RN 50-02-2 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:353292 CAPLUS <<LOGINID::20080113>>
DOCUMENT NUMBER: 136:350548
TITLE: Effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions
INVENTOR(S): Takahashi, Naoto; Weitman, Steve; D'incalci, Maurizio; Faicloth, Glynn Thomas; Giavazzi, Rafaella; Gescher, Andreas
PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002036135	A2	20020510	WO 2001-GB4902		20011106 <--
WO 2002036135	A3	20030410			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2428160	A1	20020510	CA 2001-2428160		20011106 <--
AU 200212499	A	20020515	AU 2002-12499		20011106 <--
BR 2001015162	A	20031021	BR 2001-15162		20011106 <--
EP 1365808	A2	20031203	EP 2001-980710		20011106 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004517056	T	20040610	JP 2002-538946		20011106 <--
HU 2004000648	A2	20040628	HU 2004-648		20011106 <--
NZ 525730	A	20041224	NZ 2001-525730		20011106 <--
NO 2003002027	A	20030704	NO 2003-2027		20030506 <--
MX 2003PA03975	A	20040212	MX 2003-PA3975		20030506 <--
ZA 2003003474	A	20040806	ZA 2003-3474		20030506 <--
BG 107843	A	20040630	BG 2003-107843		20030523 <--
US 2004108086	A1	20040610	US 2003-416086		20030917 <--
PRIORITY APPLN. INFO.:			US 2000-246233P	P	20001106
			US 2000-248095P	P	20001113
			US 2001-345982P	P	20011019
			WO 2001-GB4902	W	20011106

ABSTRACT:
ET-743 is used in the preparation of a medicament for an effective treatment of a tumor by combination therapy employing ET-743 with another drug.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002036135	A2	20020510	WO 2001-GB4902	20011106 <--

WO 2002036135 A3 20030410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2428160	A1	20020510	CA 2001-2428160	20011106 <--
AU 200212499	A	20020515	AU 2002-12499	20011106 <--
BR 2001015162	A	20031021	BR 2001-15162	20011106 <--
EP 1365808	A2	20031203	EP 2001-980710	20011106 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517056	T	20040610	JP 2002-538946	20011106 <--
HU 2004000648	A2	20040628	HU 2004-648	20011106 <--
NZ 525730	A	20041224	NZ 2001-525730	20011106 <--
NO 2003002027	A	20030704	NO 2003-2027	20030506 <--
MX 2003PA03975	A	20040212	MX 2003-PA3975	20030506 <--
ZA 2003003474	A	20040806	ZA 2003-3474	20030506 <--
BG 107843	A	20040630	BG 2003-107843	20030523 <--
US 2004108086	A1	20040610	US 2003-416086	20030917 <--

IT ***114899-77-3***, ET-743
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***50-02-2***, Dexamethasone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***114899-77-3***, ET-743
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

RN 114899-77-3 CAPLUS

CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT *50-02-2*, Dexamethasone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)
RN 50-02-2 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 4 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2005:4912 USPATFULL <<LOGINID::20080113>>
TITLE: Use of antitumoral compound in cancer therapy
INVENTOR(S): Jimeno, Jose, Madrid, SPAIN
Casado, Ana Ruiz, Madrid, SPAIN
Lazaro, Luis Lopez, Madrid, SPAIN
Rowensky, Eric, San Antonio, TX, UNITED STATES
Hidalgo, Manuel, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 2005004018	A1	20050106		
APPLICATION INFO.:	US 2004-492320	A1	20040818	(10)	<--

WO 2002-US33548 20021021 <--

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-348414P	20011019 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ABSTRACT:

Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2004-492320 A1 20040818 (10) <--
20021021
IT ***114899-77-3***, Ecteinascidin 743
(improved use of antitumoral compound in cancer therapy)
IT ***50-02-2*** 15663-27-1, Cisplatin 23214-92-8, Doxorubicin
33069-62-4, Paclitaxel
(improved use of antitumoral compound in cancer therapy)
IT ***114899-77-3***, Ecteinascidin 743
(improved use of antitumoral compound in cancer therapy)
RN 114899-77-3 USPATFULL
CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT ***50-02-2***
(improved use of antitumoral compound in cancer therapy)

RN 50-02-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER:	2004:142434 USPATFULL <<LOGINID::20080113>>			
TITLE:	Effective antitumor treatments			
INVENTOR(S):	Takahashi, Naoto, Tokyo, JAPAN Weitman, Steve, San Antonio, TX, UNITED STATES D'Incalci, Maurizio, Milan, ITALY Faircloth, Glynn Thomas, Cambridge, MA, UNITED STATES Giavazzi, Rafaella, Bergamo, ITALY Gescher, Andreas, Woodhouse Eves, UNITED KINGDOM			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004108086	A1	20040610	
APPLICATION INFO.:	US 2003-416086	A1	20030917 (10)	<--
	WO 2001-GB4902		20011106	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, LTD., 28 STATE STREET, 28th FLOOR, BOSTON, MA, 02109-9601			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	752			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ABSTRACT:

ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AI US 2003-416086 A1 20030917 (10) <--
20011106

IT ***114899-77-3***, ET-743
(effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***50-02-2***, Dexamethasone
(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***114899-77-3***, ET-743
(effective antitumor treatments with combinations of ET-743 with other

antitumor agents resulting in additive and synergistic interactions)

RN 114899-77-3 USPATFULL

CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT *50-02-2*, Dexamethasone

(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

RN 50-02-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 21:04:11 ON 13 JAN 2008)

     FILE 'REGISTRY' ENTERED AT 21:04:22 ON 13 JAN 2008
                E ET 743/CN
L1              1 S E3
                E DEXAMETHASONE/CN
L2              1 S E15
                E INDOLE-3-CARBINOL/CN
L3              1 S E27

     FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2, MEDLINE' ENTERED AT 21:06:42
     ON 13 JAN 2008
L4              4 S L1 AND L3
L5             26 S L1 AND L2
L6              9 S L2 AND L3
L7             35 S L4 OR L5 OR L6
L8              5 S L7 AND AY<2004
L9            281 S L3 AND (HEPATOTOXIC? OR ?TOXIC?)
                SAV L8 C10575132/A
L10           116 S L9 AND CANCER
L11            20 S L10 AND AY<2004
L12             5 S L3 (L) HEPATOTOXICITY
L13             0 S L12 AND AY<2004
L14            67 S L3 (L) LIVER
L15             0 S L14 AND AY<2004
L16            61 S L14 AND PY<2004
L17             3 S L12 AND PY<2004
```